Zephyrm Bioscience has announced its intention to pursue an initial public offering (IPO) on the Hong Kong stock exchange. The biotech company aims to secure significant funding to advance its lead cell therapy candidate, ZH901, into phase 3 clinical trials. ZH901 is targeted at treating both a
AI-Driven Collaboration Enhances Efficiency in Drug Development The landscape of drug development is undergoing a transformative shift. Today, advanced technologies like artificial intelligence (AI) are converging with traditional laboratory practices, promising a new era of efficiency and
The world of medical and pharmaceutical advancements is frequently marked by innovative partnerships that push the boundaries of what is possible in patient care. One such collaboration has recently emerged between Excellos Inc. and Galapagos. These two entities have teamed up to enhance the
Boston-based Aktis Oncology is making significant strides in the biopharmaceutical industry, standing out for its innovative efforts in developing radiopharmaceutical medicines aimed at treating cancer. The company recently secured a substantial $175 million in a Series B funding round, designed to
The biotech and pharmaceutical industries are highly dynamic fields reliant on constant innovation, robust networking, and strategic investor relations. Professionals in these sectors must attend top biopharma conferences to keep pace with the latest advancements, regulatory trends, and emerging
Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, has reached a significant milestone in the development of treatments for post-traumatic stress disorder (PTSD). The company recently announced a Material Transfer Agreement (MTA) with the U.S. Army Medical
